Keynote A39: Enfortumab Vedotin + Pembrolizumab agroundbreaking First Line Treatment in Untreated la/mUC
For over four decades, chemotherapy has been the cornerstone of treatment in locally advanced or
metastatic urothelial carcinoma. Today, we are at the cusp of a transformative shift. A groundbreaking combination therapy has emerged, achieving a notable 55% reduction in progression rates and an over 50% decrease in the risk of mortality. Dr. Thomas Powles states that if given the opportunity, he would change his treatment for these patients tomorrow.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.